AZ’ Tudorza hits study goals in COPD patients with CV risk factors

5th December 2017 Uncategorised 0

AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.

More: AZ’ Tudorza hits study goals in COPD patients with CV risk factors
Source: News